MedTrace Logo

Prospective Cohort for Adult Hemophagocytosis

NCT03117010 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2026-04-24

No results posted yet for this study

Summary

This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.

Conditions

  • Hemophagocytic Lymphohistiocytoses

Interventions

DRUG

Steroids

High dose dexamethasone 20 mg PO or IV

DRUG

Etoposide

Etoposide 150mg/BSA

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Seok Jin Kim, MD, PhD · Samsung Medical Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03117010 on ClinicalTrials.gov